Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 04, 2020 08:00 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio Announces Multiple Aldafermin Presentations at Upcoming AASLD The Liver Meeting®, including Late-Breaking Oral Presentation of 24-Week Phase 2 Study (Cohort 4) of Aldafermin in Patients with NASH

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics...
October 19, 2020 07:00 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Expands Oncology Portfolio with First Immuno-Oncology Development Candidate, NGM707, a Novel Dual Antagonist Antibody Inhibiting ILT2 and ILT4

ILT2 and ILT4, key myeloid and lymphoid checkpoints, may restrict anti-tumor immunity, enable tumors to evade immune detection and contribute to T cell checkpoint resistanceCompany plans to initiate...
August 29, 2020 07:20 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio Presents Comprehensive Findings from 24-Week Phase 2 Study (Cohort 4) of Aldafermin in Oral Plenary Presentation at The Digital International Liver Congress™ (ILC) 2020 and Announces Enrollment Completed in Phase 2b ALPINE 2/3 Study

Late-breaker presentation selected as “Best of ILC”The 24-week Phase 2 study met its primary endpoint, achieving a statistically significant reduction in liver fat content (LFC), and robust fibrosis...
August 18, 2020 08:00 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio Announces Oral Plenary Presentation of 24-Week Phase 2 Study (Cohort 4) of Aldafermin in Patients with NASH at The Digital International Liver Congress™ (ILC) 2020

SOUTH SAN FRANCISCO, Calif., Aug. 18, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative...
August 12, 2020 16:05 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio Provides Business Highlights and Reports Second Quarter 2020 Financial Results

--Sustained progress across clinical development programs spanning liver, retinal and metabolic diseases and cancer-- --Aldafermin continues to advance toward late-stage clinical development in...
July 31, 2020 08:00 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio to Present at Two Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., July 31, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative...
July 27, 2020 08:00 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio Announces Initiation of Phase 2 CATALINA Study of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

-- Multicenter, randomized, double-masked, sham-controlled study will evaluate safety and efficacy of intravitreal injections of NGM621 every four or eight weeks for 48 weeks -- -- GA is a...
June 08, 2020 08:00 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio Expands Board of Directors with Appointment of Carole Ho, M.D.

SOUTH SAN FRANCISCO, Calif., June 08, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative...
May 29, 2020 16:05 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio to Present at Two Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., May 29, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on developing transformative therapeutics for patients,...
May 27, 2020 16:05 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio Appoints Siobhan Nolan Mangini as Chief Financial Officer

SOUTH SAN FRANCISCO, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on developing transformative therapeutics for...